Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with...

Area of Science:

• Cardiology
• Clinical Diagnostics
• Biomarker Research

Background:

• Increasing sensitivity of troponin assays is standard practice.
• Clinical impact of reduced troponin detection thresholds remains unclear for acute coronary syndrome (ACS) patients.

Purpose of the Study:

• To evaluate if a lower diagnostic threshold for myocardial infarction (MI) using a sensitive troponin assay improves clinical outcomes.
• To assess the impact of implementing a sensitive troponin I assay with a reduced detection threshold on patient morbidity and mortality.

Main Methods:

• Prospective study comparing patients before and after lowering the troponin I detection threshold from 0.20 to 0.05 ng/mL.
• Stratification of patients into three groups based on troponin concentrations: <0.05 ng/mL, 0.05-0.19 ng/mL, and ≥0.20 ng/mL.
• One-year event-free survival (recurrent MI and death) was the primary outcome measure.

Main Results:

• Lowering the threshold identified more patients with MI.
• Patients with troponin concentrations of 0.05-0.19 ng/mL had a 39% rate of death or recurrent MI before threshold reduction.
• After lowering the threshold, this group showed a significant reduction in adverse events (21%), with an odds ratio of 0.42 for death and recurrent MI.

Conclusions:

• Implementing a sensitive troponin assay and lowering the diagnostic threshold increases MI diagnosis.
• This strategy effectively identifies high-risk ACS patients.
• Lowering the plasma troponin threshold is associated with substantial reductions in major adverse cardiovascular events.